Potent and selective ErbB2 inhibitor (IC50
= 10 nM). Exhibits 500-1000-fold selectivity for ErbB2 over ErbB1 and other related RTKs. Induces G1
cell cycle arrest in an ErbB2-overexpressing human cancer cell line. Promotes tumor apoptosis. Induces tumor regression in a human tumor xenograft model. Displays no apparent toxic effect on cardiac tissue.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from Pfizer Inc.
Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
Jani et al.
Cancer Res., 2007;67:9887